{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:09:33Z","timestamp":1792058973560,"version":"4.4.0"},"reference-count":40,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2967\/jnumed.122.263861","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:45:10Z","timestamp":1658425510000},"page":"1316-1322","source":"Crossref","is-referenced-by-count":33,"title":["Antibody Engineering for Nuclear Imaging and Radioimmunotherapy"],"prefix":"10.2967","volume":"63","author":[{"given":"Cindy","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Sarrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi M.","family":"Kein\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Zeglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"2022090212401061000_63.9.1316.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1957.tb49702.x"},{"key":"2022090212401061000_63.9.1316.2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0025-7125(16)33169-8","article-title":"Monoclonal immunoglobulins in cancer","volume":"50","author":"Miller","year":"1966","journal-title":"Med Clin North Am."},{"key":"2022090212401061000_63.9.1316.3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/jlcr.3628","article-title":"Understanding the in\u00a0vivo fate of radioimmunoconjugates for nuclear imaging","volume":"61","author":"Vivier","year":"2018","journal-title":"J Labelled Compd Radiopharm."},{"key":"2022090212401061000_63.9.1316.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.189944"},{"key":"2022090212401061000_63.9.1316.5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/cancers12030651","article-title":"Affibody molecules as targeting vectors for PET imaging","volume":"12","author":"Tolmachev","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2022090212401061000_63.9.1316.6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2174\/1381612822666161208121829","article-title":"DARPins bioengineering and its theranostic approaches: emerging trends in protein engineering","volume":"23","author":"Rasool","year":"2017","journal-title":"Curr Pharm Des."},{"key":"2022090212401061000_63.9.1316.7","first-page":"55","article-title":"Therapeutic antibody engineering and selection strategies","volume":"171","author":"Ministro","year":"2020","journal-title":"Adv Biochem Eng Biotechnol."},{"key":"2022090212401061000_63.9.1316.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8958-4_1","article-title":"Human monoclonal antibodies: the benefits of humanization","volume":"1904","author":"Waldmann","year":"2019","journal-title":"Methods Mol Biol."},{"key":"2022090212401061000_63.9.1316.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0261"},{"key":"2022090212401061000_63.9.1316.10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00259-018-4214-x","article-title":"18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice","volume":"46","author":"Zettlitz","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401061000_63.9.1316.11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","article-title":"Evaluation of an anti-HER2 nanobody labeled with 225Ac for targeted alpha-particle therapy of cancer","volume":"15","author":"Pruszynski","year":"2018","journal-title":"Mol Pharm."},{"key":"2022090212401061000_63.9.1316.12","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41598-022-07006-9","article-title":"Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers","volume":"12","author":"Feng","year":"2022","journal-title":"Sci Rep."},{"key":"2022090212401061000_63.9.1316.13","first-page":"1484","article-title":"Therapeutic efficacy of single-dose iso-[211At]SAGMB-anti-HER2 sdAb in mice with subcutaneous HER2-expressing breast carcinoma xenografts","volume":"62(suppl 1)","author":"Feng","year":"2021","journal-title":"J Nucl Med."},{"key":"2022090212401061000_63.9.1316.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176206"},{"key":"2022090212401061000_63.9.1316.15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pros.24294","article-title":"Pilot study of the diagnostic utility of 89Zr-df-IAB2M and 68Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer","volume":"82","author":"Vlachostergios","year":"2022","journal-title":"Prostate."},{"key":"2022090212401061000_63.9.1316.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229781"},{"key":"2022090212401061000_63.9.1316.17","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.7150\/thno.49422","article-title":"First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers","volume":"10","author":"Scott","year":"2020","journal-title":"Theranostics."},{"key":"2022090212401061000_63.9.1316.18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11307-015-0920-y","article-title":"Site-specifically labeled immunoconjugates for molecular imaging\u2014part 2: peptide tags and unnatural amino acids","volume":"18","author":"Adumeau","year":"2016","journal-title":"Mol Imaging Biol."},{"key":"2022090212401061000_63.9.1316.19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/ph14060550","article-title":"Site-specific radiolabeling of a human PD-L1 nanobody via maleimide-cysteine chemistry","volume":"14","author":"Chigoho","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2022090212401061000_63.9.1316.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0299"},{"key":"2022090212401061000_63.9.1316.21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.0c00100","article-title":"Site-specific 89Zr- and 111In-radiolabeling and in\u00a0vivo evaluation of glycan-free antibodies by azide-alkyne cycloaddition with a non-natural amino acid","volume":"31","author":"Ahn","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2022090212401061000_63.9.1316.22","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1039\/D1SC01422F","article-title":"Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor","volume":"12","author":"Rudd","year":"2021","journal-title":"Chem Sci."},{"key":"2022090212401061000_63.9.1316.23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/biom10101388","article-title":"Anti-human PD-L1 nanobody for immuno-PET imaging: validation of a conjugation strategy for clinical translation","volume":"10","author":"Bridoux","year":"2020","journal-title":"Biomolecules."},{"key":"2022090212401061000_63.9.1316.24","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201004243"},{"key":"2022090212401061000_63.9.1316.25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1015"},{"key":"2022090212401061000_63.9.1316.26","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0180-0"},{"key":"2022090212401061000_63.9.1316.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223636"},{"key":"2022090212401061000_63.9.1316.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262383"},{"key":"2022090212401061000_63.9.1316.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0311"},{"key":"2022090212401061000_63.9.1316.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918744117"},{"key":"2022090212401061000_63.9.1316.31","doi-asserted-by":"crossref","first-page":"1966970","DOI":"10.1080\/2162402X.2021.1966970","article-title":"In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart","volume":"10","author":"Man","year":"2021","journal-title":"OncoImmunology."},{"key":"2022090212401061000_63.9.1316.32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11307-014-0733-4","article-title":"A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts","volume":"16","author":"Rochefort","year":"2014","journal-title":"Mol Imaging Biol."},{"key":"2022090212401061000_63.9.1316.33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13550-020-00685-3","article-title":"177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma","volume":"10","author":"Delage","year":"2020","journal-title":"EJNMMI Res."},{"key":"2022090212401061000_63.9.1316.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2918"},{"key":"2022090212401061000_63.9.1316.35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7534"},{"key":"2022090212401061000_63.9.1316.36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroimage.2017.01.004","article-title":"A bispecific tribody PET radioligand for visualization of amyloid-beta protofibrils: a new concept for neuroimaging","volume":"148","author":"Syv\u00e4nen","year":"2017","journal-title":"Neuroimage."},{"key":"2022090212401061000_63.9.1316.37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current landscape in clinical pretargeted radioimmunoimaging and therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J Nucl Med."},{"key":"2022090212401061000_63.9.1316.38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-020-04989-3","article-title":"Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study","volume":"48","author":"Touchefeu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401061000_63.9.1316.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236000"},{"key":"2022090212401061000_63.9.1316.40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0353"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.263861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:44:12Z","timestamp":1662133452000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.263861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2967\/jnumed.122.263861"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.263861","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}